Breakthrough Science Program

Breakthrough Science Program is sponsored by EQT Foundation. This program awards catalytic grants to researchers tackling urgent challenges in the field of rare diseases.

It supports translational research at the intersection of deeptech innovation and clinical application, focusing on novel therapeutic platforms, biomarker discovery and diagnostics, trial acceleration (including registries, digital biomarkers, and AI-enabled evidence generation), access-enabling technologies, and human-relevant disease models.

EQT Foundation opens applications for breakthrough research grant in rare diseases Oops, something went wrong This is a paid press release. Contact the press release distributor directly with any inquiries.

EQT Foundation opens applications for breakthrough research grant in rare diseases September 2, 2025 3 min read EQT Foundation opens applications for deeptech solutions grant, tackling transforming how we diagnose, treat, and manage rare conditions The program will award between EUR 25,000 to EUR 100 ,000 STOCKHOLM , Sept.

2, 2025 /PRNewswire/ -- EQT Foundation is launching a new call for proposals under its Breakthrough Science program. The program awards catalytic grants of €25,000 to €100,000 to researchers tackling urgent challenges in the field of rare diseases. Designed to accelerate bold scientific ideas with high potential for real-world patient impact, the program supports translational research that might be overlooked by traditional funders.

The call is open to scientists affiliated with accredited nonprofit institutions globally. More than 300 million people worldwide live with a rare disease, nearly half of them children¹. For most, the path to diagnosis is long and uncertain, and treatment options are limited or nonexistent.

At the same time, the rare disease field has given rise to some of the most significant advances in medicine, from gene therapy to RNA-based modulation. This grant call aims to support the next generation of these breakthroughs, solutions that begin with the rare few but ripple across science and healthcare systems at large.

The program seeks research at the intersection of deeptech innovation and clinical application, with a focus on: Novel therapeutic platforms: gene and RNA therapies, enzyme replacement, oral treatments, delivery innovations, and scalable approaches to individualized medicine Biomarker discovery and diagnostics: tools that accelerate early detection and improve trial design, especially in underserved settings Trial acceleration: registries, digital biomarkers, and AI-enabled evidence generation for faster paths to first-in-patient Access-enabling technologies: innovations that reduce cost or complexity of deployment in low-resource or remote settings Human-relevant disease models: induced pluripotent stem cells, organoids, or organ-on-chip platforms that deepen mechanistic insight and de-risk clinical development Cilia Holmes Indahl, CEO, EQT Foundation, comments: "Rare diseases often go unseen and unheard, leaving millions, many of them children, without effective treatments or timely diagnoses.

Through this fast-track grant program, we're not just funding research, we're supporting bold scientists to make the leap from lab to clinic. We believe breakthrough technologies can help improve treatments for rare diseases in cost-effective ways, representing an interesting new area for impact investors looking to improve quality-adjusted life years."

In addition to funding, the grantees will benefit from access to EQT's global network, connecting them with advisors, potential industry partners, and commercialization support tailored to the needs of translational science. Applications open on September 2, 2025 , and close on October 1, 2025 , at 23:59 CET . Proposals will be reviewed by a panel of scientific and translational experts.

Shortlisted applicants will be invited to interview with the EQT Foundation team, with final decisions communicated shortly thereafter. To apply, visit: https://eqtgroup. com/eqt-foundation/grant-submission 1 United Nations General Assembly, Addressing the Challenges of Persons Living with a Rare Disease and Their Families (A/RES/76/132), 2021 This information was brought to you by Cision http://news.

cision. com https://news. cision.

com/eqt/r/eqt-foundation-opens-applications-for-breakthrough-research-grant-in-rare-diseases,c4228486 The following files are available for download: https://mb. cision. com/Main/87/4228486/3644027.

pdf EQT Foundation opens applications for breakthrough research grant in rare diseases https://news. cision. com/eqt/i/eqt-foundation,c3466154 Cision View original content: https://www.

prnewswire. co. uk/news-releases/eqt-foundation-opens-applications-for-breakthrough-research-grant-in-rare-diseases-302543786.

html EQT Foundation opens applications for science grants to overcome the blood-brain barrier and transform CNS drug delivery Qure.

ai Secures Major Global Health Grant to Build AI-Powered Point-of-Care Ultrasound Healx raises $56M Series B to use AI to find treatments for rare diseases San Diego-Area Biotech Startup Achieves Major Breakthrough in the Fight Against Rare Neurodevelopmental Disorder P4ML Becomes Founding Member of Orphan Therapeutics Accelerator (OTXL) to Support Broader Global Access to Ultra-Rare Disease Treatments TIME Names GeneDx CEO Katherine Stueland to the 2026 TIME100 Health List of the World’s Most Influential Leaders in Health Rare Disease Campaign Launches Nationwide EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics ASGCT and Orphan Therapeutics Accelerator Launch CGTxchange -- A First-of-Its-Kind Marketplace to Reactivate Promising Shelved Cell and Gene Therapy Programs Mark Zuckerberg and Dr. Priscilla Chan’s plan to prevent, cure, and manage all diseases by 2100